Financing channel feed

Gold­man Sachs clos­es $650M life sci­ences fund to bankroll in­dus­try’s ‘gold­en era’

Last year
Startups

Roche lines up RNA pact with Remix Ther­a­peu­tics, which al­so raised an­oth­er $60M

Last year
Startups
Deals

Blad­der can­cer drug­mak­er CG On­col­o­gy files for IPO as biotech mar­ket shows signs of a re­bound

Last year

Im­mu­ni­ty­Bio inks roy­al­ty deal, pri­vate place­ment to raise $210M for blad­der can­cer drug com­bo

Last year
Deals

Verona se­cures $400M fi­nanc­ing arrange­ment with Ox­ford, Her­cules as en­sifen­trine PDU­FA date inch­es clos­er

Last year
R&D

Tonix rais­es $144M in a di­rect of­fer­ing fol­low­ing pos­i­tive PhI­II da­ta for its fi­bromyal­gia drug

Last year
R&D

Ex­clu­sive: Su­do Bio­sciences se­cures $116M to start tri­als of its oral and top­i­cal TYK2 can­di­dates

Last year
Startups

Lassen Ther­a­peu­tics reels in $85M Se­ries B for PhII test­ing in thy­roid eye dis­ease

Last year
Startups

Ex­clu­sive: Kimia Ther­a­peu­tics se­cures $55M to su­per­charge co-founder’s plat­form, cre­ate ‘next-gen­er­a­tion Car­mot’

Last year
Startups

Blue­bird in fundrais­ing mode: A $150M pub­lic of­fer­ing and a deal to get cash ear­ly from gene ther­a­py sales

Last year
Deals

VC firm Piv­otal clos­es sec­ond $389M ther­a­peu­tics fund to cre­ate com­pa­nies and back pub­lic biotechs

Last year

To­tus Med­i­cines clos­es $66M Se­ries B to fund ear­ly-stage PI3Ka in­hibitor, names new CEO

Last year
Startups

Q&A: JP Mor­gan’s new life sci­ences pri­vate cap­i­tal leader on the bank’s ex­pand­ing am­bi­tions, vet­ting star­tups and Abu Dhabi’s biotech push

Last year
People

Bet­ting on pub­lic mar­ket de­mand for more obe­si­ty ther­a­pies, Fractyl Health files for IPO to back gene ther­a­py

Last year
Cell/Gene Tx

'Won­der­ful Christ­mas gift': Fed's sur­prise rate-cut plan springs hope of 2024 biotech mar­ket re­bound

Last year
Deals
Pharma

Play­ground rais­es $410M fund, Ar­tis clos­es $200M as bi­ol­o­gy and tech VC con­ver­gence con­tin­ues

Last year
Startups

For­mer ex­ecs from Pfiz­er obe­si­ty drug pro­gram have start­ed a new biotech with $52M from VC fund ATP

Last year
Startups
AI

Up­dat­ed: Meta­bol­ic drug de­vel­op­er High­T­ide Ther­a­peu­tics eyes $36M raise with HK IPO

Last year

En­cellin rais­es about $10M for type 1 di­a­betes cell re­place­ment ther­a­py

Last year

Im­munother­a­py biotech rais­es $37M from back­ers like Pfiz­er, Take­da, BMS

Last year

MIT gene edit­ing spin­out launch­es with $213M to write the 'fi­nal chap­ter in ge­nom­ic med­i­cine'

Last year
Startups
Cell/Gene Tx

Ex­clu­sive: Shi­no­bi rais­es $51M to take on cell ther­a­py chal­lenges with ex-Wu­gen CEO at helm, Carl June in sup­port

Last year
Startups
Cell/Gene Tx

Ex­clu­sive: Women’s health biotech Freya Bio­sciences rais­es $38M for mi­cro­bial im­munother­a­pies

Last year
Startups

Bio­con on­col­o­gy spin­out Bicara se­cures its sec­ond nine-fig­ure fi­nanc­ing of the year

Last year
Startups
First page Previous page 21222324252627 Next page Last page
A service from the Financial Times